Noyem Global

Noyem Global is a biotechnology company focused on developing innovative solutions for the delivery of therapeutic agents across the blood-brain barrier (BBB). The company utilizes a proprietary platform based on engineered protein shuttles that leverage receptor-mediated transcytosis, specifically targeting the insulin-like growth factor 1 receptor (IGF1R). This technology enables the transport of various modalities, including small molecules and large biologics, into the central nervous system (CNS) with high efficiency. Noyem Global's pipeline is primarily directed toward high-unmet-need areas such as neuro-oncology and rare metabolic disorders that affect the brain. By overcoming the challenge of the BBB, the company aims to transform the treatment landscape for glioblastoma and other debilitating CNS conditions.